We evaluated whether the overexpression of DLEU2L impairs pancreatic cancer progression in vitro and tumor development in vivo using a nude mouse xenograft model, by examining cancer cell proliferation, apoptosis, glucose metabolism, drug resistance, and molecular signaling pathways. Here, DLEU2L is linked to pancreatic neoplasm.